Forte Biosciences, Inc. has entered into a Securities Purchase Agreement to sell approximately 4.93 million shares of common stock and pre-funded warrants for gross proceeds of about $53 million, with participation from executive officers totaling $475,000. The private placement is expected to close on November 21, 2024, and proceeds will be used for working capital and corporate purposes.